You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 11,235,169


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,235,169 protect, and when does it expire?

Patent 11,235,169 protects AMELUZ and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 11,235,169
Title:Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device
Abstract: An Illumination device (100) for photodynamic therapy is provided, the illumination device comprising at least one electromagnetic radiation emitting unit (10), the at least one electromagnetic radiation emitting unit comprising at least one electromagnetic radiation source (1), the electromagnetic radiation source being configured to generate radiation for the irradiation of a region of an irradiation object in an illumination session, wherein the irradiation object is to be arranged at a predetermined object location (300), wherein the predetermined object location is arranged at a distance relative to a radiation output area (11) of the radiation emitting unit through which the radiation generated by the at least one electromagnetic radiation source exits the radiation emitting unit during operation of the illumination device (100).
Inventor(s): Osterloh; Markus (Leverkusen, DE), Novak; Ben (Leverkusen, DE), Lubbert; Hermann (Leverkusen, DE)
Assignee: BIOFRONTERA PHARMA GMBH (Leverkusen, DE)
Application Number:17/215,785
Patent Claim Types:
see list of patent claims
Use; Composition; Device;

Drugs Protected by US Patent 11,235,169

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biofrontera AMELUZ aminolevulinic acid hydrochloride GEL;TOPICAL 208081-001 May 10, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up TOPICAL LESION-DIRECTED AND FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS OF THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY BY POSITIONING AN ILLUMINATION DEVICE IN AN APPROPRIATE DISTANCE AND ILLUMINATING THE TREATMENT AREA WITH NARROWBAND RED LIGHT ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,235,169

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 3195112 ⤷  Sign Up
China 116507387 ⤷  Sign Up
European Patent Office 4228745 ⤷  Sign Up
Japan 2023545490 ⤷  Sign Up
South Korea 20230088755 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2022078955 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.